Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone or Ziprasidone to Reduce Oxycodone Abuse Liability
NCT04587115Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risperidone and ziprasidone in opioid use disorder (OUD) (3 arms), sponsored by UT Health San Antonio. Primary endpoint: Evaluation of analgesic efficacy - Cold pressor at 2 weeks. Started Jun 2017; status: completed.
02
Drugs
risperidoneziprasidone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04587115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587115.